Update on the Treatment of Patients With Non–Genotype 1 Hepatitis C Virus Infection
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on the Treatment of Patients With Non–Genotype 1 Hepatitis C Virus Infection
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume 56, Issue 9, Pages 1294-1300
Publisher
Oxford University Press (OUP)
Online
2012-12-28
DOI
10.1093/cid/cis1195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
- (2012) Jean-Michel Pawlotsky et al. ANTIVIRAL THERAPY
- HCV Infection and Metabolic Syndrome: Which Is the Chicken and Which Is the Egg?
- (2012) Francesco Negro GASTROENTEROLOGY
- 1135 IL28B CC GENOTYPE IS ASSOCIATED WITH HIGHER ON-TREATMENT-RESPONSE RATES IN PTS WITH HCV-3: INTERIM RESULTS OF THE WRITE STUDY
- (2012) V. Piazzolla et al. JOURNAL OF HEPATOLOGY
- 1113 ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3
- (2012) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
- (2011) Graham R. Foster et al. GASTROENTEROLOGY
- Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future
- (2011) Vincent Di Martino et al. HEPATOLOGY
- IL28Bgenetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
- (2011) Amir Moghaddam et al. HEPATOLOGY
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C
- (2011) Michael Manns et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2011) JOURNAL OF HEPATOLOGY
- Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
- (2011) Magnus Lindh et al. JOURNAL OF INFECTIOUS DISEASES
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
- (2011) Markus Cornberg et al. LIVER INTERNATIONAL
- Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
- (2010) Fabrizio Mecenate et al. BMC GASTROENTEROLOGY
- An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
- (2010) Alessandra Mangia et al. GASTROENTEROLOGY
- Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
- (2010) Moises Diago et al. HEPATOLOGY
- Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3
- (2010) Alessandra Mangia et al. JOURNAL OF HEPATOLOGY
- Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
- (2010) Thomas-Matthias Scherzer et al. JOURNAL OF HEPATOLOGY
- Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
- (2010) Christoph Sarrazin et al. JOURNAL OF HEPATOLOGY
- Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
- (2010) Michael W. Fried et al. JOURNAL OF HEPATOLOGY
- Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel
- (2010) Mahmoud A. Khattab et al. JOURNAL OF HEPATOLOGY
- Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
- (2009) Thierry Poynard et al. GASTROENTEROLOGY
- Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis
- (2009) Savino Bruno et al. HEPATOLOGY
- 10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS
- (2009) Y. Benhamou et al. JOURNAL OF HEPATOLOGY
- Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
- (2009) Pierre-Yves Bochud et al. JOURNAL OF HEPATOLOGY
- Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
- (2008) Alessandra Mangia et al. HEPATOLOGY
- Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
- (2008) Martin Lagging et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation